RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to unmask lymphoma cells to the immune system
Disease control OngoingThis study tests a combination of two drugs, TTI-622 and pembrolizumab, in people with diffuse large B-cell lymphoma that has returned or stopped responding to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune system, while pembrolizuma…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial studies whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can safely improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. The drug is designed to boost the immune system's c…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC